• Something wrong with this record ?

Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers

K. Stanek, M. Zimovjanova, P. Suk, F. Jonas, A. Zimovjanova, M. Molitor, O. Mestak

. 2022 ; 46 (2) : 706-711. [pub] 20210803

Language English Country United States

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 2002-11-01 to 1 year ago
Medline Complete (EBSCOhost) from 2003-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2002-11-01 to 1 year ago

BACKGROUND: Mutations in the BRCA1 or BRCA2 genes increase the lifetime risk of developing breast cancer to 68-72% by the age of 80. One of the modalities to manage the risk is a prophylactic mastectomy. Bilateral nipple-sparing mastectomy specifically offers the most favorable esthetic outcomes but the evidence for its oncological safety remains limited. Thus, we aimed to compare the occurrence of breast cancer between nipple-sparing mastectomy and surveillance groups of BRCA1 or BRCA 2 mutations carriers. MATERIALS AND METHODS: BRCA1 or BRCA2-positive patients undergoing bilateral prophylactic nipple-sparing mastectomy at our department were identified. Only those unaffected by breast cancer were eligible. Each patient was pair-matched with a BRCA1 or BRCA2-positive patient of equal age from the surveillance group. Breast cancer incidence in both groups was recorded and the results were compared. RESULTS: None of 105 patients who underwent NSM between 2009 and 2019 at a single institution with a mean follow-up time of 50 months developed breast cancer over this time period. One patient in this group died of an unrelated cause. Nine patients from 105 in the match-paired surveillance group were diagnosed with breast cancer during a mean follow-up time of 58.3 months, however, none of them died. CONCLUSION: To the best of our knowledge, this is the largest single-center study of risk-reducing bilateral NSM in healthy BRCA1 or BRCA2 mutation carriers. Based on our results and those of other series, we conclude that NSM in its current form appears to be at least equally as safe as other types of mastectomy for preventing breast cancer in BRCA1 or BRCA2 mutation carriers. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018892
003      
CZ-PrNML
005      
20231005102340.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00266-021-02506-x $2 doi
035    __
$a (PubMed)34342702
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Staněk, Kryštof $u Department of Plastic Surgery, Bulovka Hospital, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0307909
245    10
$a Bilateral Prophylactic Nipple-Sparing Mastectomy: Analysis of the Risk-Reducing Effect in BRCA1/2 Mutation Carriers / $c K. Stanek, M. Zimovjanova, P. Suk, F. Jonas, A. Zimovjanova, M. Molitor, O. Mestak
520    9_
$a BACKGROUND: Mutations in the BRCA1 or BRCA2 genes increase the lifetime risk of developing breast cancer to 68-72% by the age of 80. One of the modalities to manage the risk is a prophylactic mastectomy. Bilateral nipple-sparing mastectomy specifically offers the most favorable esthetic outcomes but the evidence for its oncological safety remains limited. Thus, we aimed to compare the occurrence of breast cancer between nipple-sparing mastectomy and surveillance groups of BRCA1 or BRCA 2 mutations carriers. MATERIALS AND METHODS: BRCA1 or BRCA2-positive patients undergoing bilateral prophylactic nipple-sparing mastectomy at our department were identified. Only those unaffected by breast cancer were eligible. Each patient was pair-matched with a BRCA1 or BRCA2-positive patient of equal age from the surveillance group. Breast cancer incidence in both groups was recorded and the results were compared. RESULTS: None of 105 patients who underwent NSM between 2009 and 2019 at a single institution with a mean follow-up time of 50 months developed breast cancer over this time period. One patient in this group died of an unrelated cause. Nine patients from 105 in the match-paired surveillance group were diagnosed with breast cancer during a mean follow-up time of 58.3 months, however, none of them died. CONCLUSION: To the best of our knowledge, this is the largest single-center study of risk-reducing bilateral NSM in healthy BRCA1 or BRCA2 mutation carriers. Based on our results and those of other series, we conclude that NSM in its current form appears to be at least equally as safe as other types of mastectomy for preventing breast cancer in BRCA1 or BRCA2 mutation carriers. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    12
$a nádory prsu $x genetika $x prevence a kontrola $x chirurgie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a subkutánní mastektomie $x metody $7 D015414
650    _2
$a mutace $7 D009154
650    _2
$a prsní bradavky $x chirurgie $7 D009558
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zimovjanova, Martina $u First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Oncology, General University Hospital, Prague, Czech Republic
700    1_
$a Suk, Petr $u Department of Plastic Surgery, Bulovka Hospital, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Jonas, Filip $u Department of Plastic Surgery, Bulovka Hospital, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zimovjanova, Anna $u Faculty of Medicine, Masaryk University, Brno, Czech Republic $u International Clinical Research Center (ICRC), St Anne's University Hospital (FNUSA) Brno, Brno, Czech Republic
700    1_
$a Molitor, Martin $u Department of Plastic Surgery, Bulovka Hospital, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mestak, Ondrej $u Department of Plastic Surgery, Bulovka Hospital, Prague, Czech Republic. mestak@gmail.com $u First Faculty of Medicine, Charles University, Prague, Czech Republic. mestak@gmail.com $1 https://orcid.org/0000000232131051
773    0_
$w MED00005691 $t Aesthetic plastic surgery $x 1432-5241 $g Roč. 46, č. 2 (2022), s. 706-711
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34342702 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20231005102335 $b ABA008
999    __
$a ok $b bmc $g 1822468 $s 1170135
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 46 $c 2 $d 706-711 $e 20210803 $i 1432-5241 $m Aesthetic plastic surgery $n Aesthetic Plast Surg $x MED00005691
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...